Barasertib Completed Phase 1 Trials for Acute Myeloid Leukemia (AML) Treatment

CompletedTreatment1 IdentifierTitleDrugs
NCT00926731Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
NCT00530699Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
NCT01019161An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)